查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2086952

多種癌症的早期檢測：市場洞察、競爭格局和市場預測（2034 年）

Multi-Cancer Early Detection - Market Insights, Competitive Landscape, and Market Forecast - 2034
出版日期: | 出版商: DelveInsight | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

多癌種早期檢測市場概述

概述：

  • 預計到 2025 年，多癌種早期檢測市場規模將達到 15.5 億美元，到 2034 年將達到 58.5 億美元。這一成長是由全球癌症負擔加重、基於血液的液態生物檢體篩檢技術日趨成熟以及與單次檢測多癌種相關的大規模不斷增加所推動的。
  • 全球多種癌症早期檢測市場預計在 2026 年至 2034 年的預測期內將以 15.9% 的複合年成長率成長。
  • 按技術分類，預計到 2025 年，液態生物檢體領域將佔 61% 的市場佔有率，從而推動多癌種早期檢測市場的發展。
  • 按檢測類型分類，實驗室自建檢測 (LDT) 預計到 2025 年將佔 68% 的市場佔有率，引領多癌種早期檢測市場。
  • 就檢體類型而言，預計到 2025 年，血液樣本將佔市場佔有率的 82%，引領多癌種早期檢測市場。
  • 按最終用戶分類，預計到 2025 年，醫院和診所將佔市場佔有率的 46%，引領多癌種早期檢測市場。
  • 到 2025 年，北美將佔全球多癌種早期檢測市場佔有率的 58%，成為全球市場佔有率最高的地區。

多重癌症早期檢測 (MCED) 是指同時篩檢多種癌症類型的訊號，通常只需一份血液樣本，即可實現惡性腫瘤的早期發現，包括目前尚無成熟篩檢方案的癌症。 MCED 檢測分析血液中腫瘤來源的生物標記物，例如遊離 DNA 的甲基化模式、片段組體學、突變和蛋白質，並應用機器學習技術來檢測癌症訊號，通常還能預測原發組織。基於液態生物檢體、次世代定序、多組體學和人工智慧技術的進步，這些檢測方法能夠從一份非侵入性檢體中檢測出數十種其他癌症類型，從而補充了現有的乳癌、子宮頸癌、結直腸癌和肺癌等單一癌症篩檢。該市場涵蓋液態生物檢體和其他技術、檢查室開發和監管機構已通過核准的檢測類型、血液和其他檢體類型，以及在醫院、診所、診斷檢查室、學術和研究機構的應用。以 GRAIL 的「Galleri」、Exact Sciences 的「Cancerguard」和 Guardant Health 的血液篩檢等測試為核心，並藉助大規模註冊試驗、FDA 申請以及保險公司和雇主日益成長的興趣，MCED 已成為癌症篩檢和精準腫瘤學領域最具變革性和最引人注目的前沿領域之一。

多癌種早期檢測市場的主要市場促進因素

  • 全球癌症負擔日益加重，導致對早期檢測的需求不斷成長。國際癌症研究機構（IARC）預測，癌症患者人數將從2022年的2,000萬增加到2050年的3,500萬，每年約有1,000萬人死於癌症。
  • 液態生物檢體和多體學技術的成熟使得透過一次血液樣本檢測多種類型的癌症成為可能，包括目前尚無建議篩檢測試的癌症。
  • 大規模招募試驗累積了臨床證據，GRAIL 的 PATHFINDER 2 試驗表明，在標準篩檢中加入 Galleri 可使癌症檢出率提高七倍以上。
  • 隨著 FDA 將其指定為“突破性設備”，以及 GRAIL 計劃於 2026 年為 Galleri 提交上市前批准申請，與監管機構的合作正在加速，MCED 正朝著正式批准和保險覆蓋邁進。
  • 隨著保險公司、雇主和醫療保健系統（例如，擁有自保計劃的雇主將 MCED 添加到其健康福利中）對 MCED 的興趣日益濃厚，商業性用途的機會正在擴大。
  • 人工智慧 (AI) 的進步提高了從甲基化、片段體學和多體學數據中檢測細微癌症訊號的準確性，從而提高了對原發組織的精確度和預測能力。
  • 癌症負擔、液態生物檢體技術的成熟、臨床證據、監管進步以及保險公司的興趣等因素綜合表明，強勁的兩位數成長將持續到 2034 年。

推動多癌種早期檢測市場成長的因素

市場促進因素

全球癌症負擔日益加重，對早期檢測的需求也日益成長。

推動多癌種早期檢測市場成長的最主要因素是全球癌症負擔日益加重以及早期檢測與存活率之間的密切關聯。根據國際癌症研究機構（IARC）的數據，2022年全球新增癌症病例達2,000萬例，預計2050年將達到3,500萬例。同時，癌症仍是全球主要死因之一，每年約造成1,000萬人死亡。大多數癌症在發現時已處於晚期，此時治療效果較差，存活率較低，絕大多數癌症類型目前尚無建議的篩檢方法。癌症的早期發現能夠顯著改善治療效果並降低治療成本，因為早期治療遠比晚期治療便宜。 MCED檢測透過一次血液樣本即可同時篩檢多種癌症，包括目前尚無篩檢方法的癌症，從而有效應對了這項挑戰。隨著人口老化、生活方式改變和環境因素導致癌症發生率上升，對更早期、更廣泛篩檢的需求將會增加，這將推動市場在2034年之前持續成長。

液態生物檢體和多體學技術的成熟

液態生物檢體和多體學技術的快速成熟是推動其成長的核心動力。次世代定序、無細胞DNA甲基化分析、片段體學以及結合DNA、RNA、蛋白質和表觀基因組標記的多分析物檢測技術的進步，使得僅需一份非侵入性血液樣本即可檢測多種癌症。液態生物檢體在基層醫療和健康篩檢尤其具有吸引力，因為在這些領域進行侵入性組織切片檢查並不現實。像Galleri這樣的旗艦檢測方法能夠從單一血液樣本中檢測出50多種癌症的訊號。定序成本的降低、多重檢測技術的改進以及新生物標記的發現，不斷提高檢測的靈敏度和特異性，同時降低價格，擴大可檢測的癌症種類和可篩檢的人群範圍。隨著這些技術的成熟和規模化應用，多組學檢測將變得更加準確、經濟和普及，從而在預測期內直接推動其在臨床和篩檢領域的應用。

市場限制因素

儘管多癌種早期檢測市場發展勢頭強勁，但仍面臨諸多限制因素。高昂的檢測費用是一大障礙，單次檢測的標價通常從幾百美元到超過1000美元不等，這對於全民篩檢而言仍然是一筆不小的負擔。此外，主要檢測項目的價格接近949美元，與乳房X光檢查和糞便檢驗相比，這一價格被保險公司視為「昂貴」。有限的保險報銷加劇了這項挑戰。大多數多癌種早期檢測項目以自費檢查室自建檢測（LDT）的形式銷售，並未被保險公司或聯邦醫療保險（Medicare）廣泛覆蓋，這意味著癌症高危險群——老年人——往往不得不自行承擔費用，而提案此類檢測納入聯邦醫療保險的立法提案尚未獲得通過。此外，大多數檢測項目尚未獲得美國食品藥物管理局（FDA）的批准，這限制了它們的推廣、保險報銷和納入臨床指南，法律規範也仍不完善。臨床方面的擔憂依然存在。這包括假陽性結果可能導致昂貴且令人焦慮的確診檢測，假陰性結果可能造成虛假的安全感，早期癌症檢測敏感性低，以及在獲得長期療效數據之前，其對癌症死亡率的實際影響不確定性。此外，市場競爭激烈，許多開發商都在追求不同的技術，因此尚不清楚哪個平台能夠取得永續的臨床和商業性成功。基礎設施的限制、臨床醫生和患者認知上的差異，以及對資料隱私和公平性的考量，都進一步限制了液體活體組織切片技術的普及，尤其是在新興市場。儘管癌症負擔沉重，液體活體組織切片技術不斷創新，但這些成本、報銷、監管、臨床和基礎設施方面的障礙，共同減緩了液態生物檢體的成長速度。

可以從以下幾個方面評估競爭格局：

  • 市場集中度：市場集中度適中，資金雄厚的大公司與許多新興的開發公司並存，主要得益於資本密集臨床證據的產生。
  • 由於大規模的資料集、商業規模和監管方面的進步，GRAIL、Exact Sciences 和 Guardant Health 等領先公司處於行業前沿。
  • 地理擴張：各大公司在國內營運檢體採集和檢測網路，並向國際擴張，其中中國、日本和東南亞的本土公司展現出實力。
  • 產品系列優勢：領先的公司擁有檢驗的通用癌症檢測和基於血液的篩檢檢測，通常還擁有針對特定癌症類型和精準腫瘤學的檢測產品組合。
  • 研發管線和證據優勢：諸如「PATHFINDER 2」和「NHS-Galleri」等大規模註冊試驗以及突破性認定，提供了決定性的競爭優勢。
  • 策略夥伴關係：我們透過與檢測網路、醫療保健系統、雇主、電子健康記錄平台和國際合作夥伴的合作，不斷擴大業務範圍。
  • 併購活動：產業重組正在積極推進，例如 GRAIL 從 Illumina 分拆出來，以及 Abbott 計劃收購 Exact Sciences。
  • 監管優勢：FDA 將 Galleri 指定為“突破性設備”，以及 GRAIL 的上市前批准申請是重要的區別因素。
  • 創新重點：甲基化和片段組體學、多體學、人工智慧驅動的訊號檢測和原代組織預測，以及低成本、擴充性的檢測方法。

多癌種早期檢測市場報告要點。

  • 對多癌種早期檢測市場的當前市場規模（2025 年）進行分析，並進行 9 年市場預測（2026 年至 2034 年）。
  • 過去三年發生的重大產品和技術開發、合併、收購、合作和合資企業。
  • 在多種癌症早期檢測領域佔據全球市場的領先公司。
  • 多癌種早期檢測市場為競爭者提供了各種機會。
  • 哪些細分市場在2025年表現最佳？這些細分市場在2034年的表現又會如何？
  • 在目前多種癌症早期檢測市場中，哪些地區和國家的表現最佳？
  • 企業應該將精力集中在哪些地區或國家，以尋求多癌種早期檢測市場的未來成長機會？

本「多種癌症早期檢測市場」報告調查的主要讀者

  • 多種癌症早期檢測產品供應商
  • 研究機構和顧問公司
  • 參與多種癌症早期檢測的組織、協會、論壇及其他相關團體。
  • 政府機構和公司
  • 新創公司、創業投資、私募股權公司
  • 銷售代理商和公司從事多種癌症的早期檢測領域
  • 各種希望了解多癌種早期檢測市場及其最新技術趨勢的終端用戶。

常問問題：

Q1. 多癌種早期檢測市場的成長率是多少？

預計從 2026 年到 2034 年的預測期內，多癌種早期檢測市場將以 15.9% 的複合年成長率成長。

Q2. 多種癌症早期檢測的市場規模有多大？

2025年，多種癌症早期檢測的市場規模估計為15.5億美元，預計到2034年將達到58.5億美元。

Q3. 哪個地區正在推動多種癌症早期檢測市場的發展？

北美擁有強大的生物技術生態系統、活躍的風險投資、早期監管合作、較高的篩檢意識，以及GRAIL、Exact Sciences和Guardant Health等領先的研發公司，預計主導多癌種早期檢測市場，到2025年將佔全球銷售額的58%。亞太地區預計將成為預測期內成長最快的地區。

第四季：多癌種早期檢測市場的主要促進因素是什麼？

主要的驅動力是全球癌症負擔日益加重。國際癌症研究機構（IARC）預測，癌症患者人數將從2022年的2,000萬人增加到2050年的3,500萬人。這主要得益於液態生物檢體和多組體學技術的成熟、PATHFINDER 2和NHS-Galleri等大型臨床試驗提供的日益豐富的臨床證據、與美國食品藥品監督管理局（FDA）加速合作（包括突破性療法認定和GRAIL的上市前批准申請），以及保險公司、雇主和醫療保健系統對這些技術的日益重視。

Q5. 多癌種早期檢測市場的主要參與者有哪些？

主要參與者包括 GRAIL 公司、Exact Sciences 公司、Guardant Health 公司、Freenome Holdings 公司、Illumina 公司、羅氏製藥（Foundation Medicine）、燃石生物技術有限公司、Natera 公司、Singlera Genomics 公司和 Delfi Diagnostics 公司，以及眾多其他活躍的研發公司，這些公司有詳細介紹這些公司在詳細的研發模式。 GRAIL 公司憑藉其「Galleri」平台和最大的 MCED 臨床資料集引領該行業，而 Guardant Health 和 Exact Sciences 公司則致力於開發基於血液的篩檢平台。

目錄

第1章：多癌種早期檢測市場報告簡介

  • 調查範圍
  • 市場區隔
  • 市場先決條件

第2章：多癌種早期檢測市場執行摘要

  • 市場概覽

第3章：多癌種早期檢測市場關鍵因素分析

  • 多癌種早期檢測市場：市場促進因素
    • 全球癌症負擔日益加重，早期檢測至關重要
    • 液態生物檢體和多體學的成熟
    • 臨床證據的累積和監管機構參與度的提高
    • 保險公司、雇主和醫療保健系統實施狀況
  • 多癌種早期檢測市場的市場限制與挑戰
    • 檢測費用高昂且保險覆蓋範圍有限。
    • 監管和臨床檢驗障礙
    • 假陽性、假陰性及確診檢測
  • 多癌種早期檢測市場：市場機會
    • 獲得FDA批准、保險報銷和聯邦醫療保險覆蓋
    • 新興市場和預防性篩檢的擴展

第4章 影響分析：人工智慧、地緣政治、貿易和經濟趨勢

第5章：監理分析

  • 美國
  • 歐洲
  • 日本
  • 中國

第6章：多癌種早期檢測市場的波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 新進入者的威脅
  • 替代品的威脅
  • 競爭公司之間的競爭

第7章：多癌種早期檢測市場評估

  • 透過技術
    • 液態生物檢體
    • 基因檢測
    • 基於蛋白質和多體學
    • 其他
  • 測試類型
    • 檢查室開發的測試
    • 監理已通過核准測試
  • 檢體型
    • 血
    • 尿
    • 唾液和其他
  • 最終用戶
    • 醫院和診所
    • 診斷檢查室
    • 學術研究機構
  • 按地區
    • 北美洲
    • 歐洲
    • 亞太地區
    • 世界其他地區

第8章：多癌種早期檢測市場的競爭格局

  • 市場集中度與結構
  • 競爭定位與市場佔有率分析（加值服務）

第9章：多癌種早期檢測市場的新創企業資金籌措與投資趨勢

第10章：多癌種早期檢測市場：公司概況與產品概況

  • GRAIL, Inc.
    • 公司簡介
    • 公司簡介
    • 財務概覽
    • 產品系列
    • 策略舉措/熵
  • Exact Sciences Corporation
  • Guardant Health, Inc.
  • Freenome Holdings, Inc.
  • Illumina, Inc.
  • F. Hoffmann-La Roche Ltd (Foundation Medicine)
  • Burning Rock Biotech Limited
  • Natera, Inc.
  • Singlera Genomics, Inc.
  • Delfi Diagnostics, Inc.

第11章：KOL的觀點

第12章：專案式教學方法

第13章：關於 DelveInsight

第14章 免責聲明與聯絡方式

Product Code: DIMDCL0939

Multi-Cancer Early Detection Market Summary

Overview:

  • The Multi-Cancer Early Detection market is estimated at USD 1.55 billion in 2025 and is projected to reach USD 5.85 billion by 2034. Growth is anchored in the rising global cancer burden, the maturation of blood-based liquid-biopsy screening, and a wave of large registrational trials and regulatory submissions for single-test, multi-cancer detection.
  • The global Multi-Cancer Early Detection market is growing at a CAGR of 15.9% during the forecast period from 2026 to 2034.
  • By technology, the liquid biopsy segment dominated the Multi-Cancer Early Detection market with a 61% share in 2025.
  • By test type, the laboratory-developed tests segment dominated the Multi-Cancer Early Detection market with a 68% share in 2025.
  • By sample type, the blood segment dominated the Multi-Cancer Early Detection market with a 82% share in 2025.
  • By end user, the hospitals and clinics segment dominated the Multi-Cancer Early Detection market with a 46% share in 2025.
  • North America dominated the global Multi-Cancer Early Detection market revenue with a 58% share in 2025, representing the highest regional market share globally.

Multi-cancer early detection (MCED) refers to tests that screen for signals from many cancer types simultaneously, typically from a single blood draw, enabling earlier detection of malignancies, including those that lack established screening programs. MCED tests analyze tumor-derived biomarkers in the blood, such as cell-free DNA methylation patterns, fragmentomics, mutations, and proteins, and apply machine learning to detect a cancer signal and often predict its tissue of origin. Built on advances in liquid biopsy, next-generation sequencing, multiomics, and artificial intelligence, these tests complement existing single-cancer screening for breast, cervical, colorectal, and lung cancers by extending detection across dozens of additional cancer types from one non-invasive sample. The market spans liquid-biopsy and other technologies, laboratory-developed and regulatory-approved test types, blood and other sample types, and applications across hospitals and clinics, diagnostic laboratories, and academic and research institutes. Anchored by tests such as GRAIL's Galleri, Exact Sciences' Cancerguard, and Guardant Health's blood-based screening, and propelled by large registrational trials, FDA submissions, and growing payer and employer interest, MCED has emerged as one of the most transformative and closely watched frontiers in cancer screening and precision oncology.

Multi-Cancer Early Detection Market Key Growth Drivers

  • The rising global cancer burden is driving demand for earlier detection, with the International Agency for Research on Cancer projecting cancer cases to rise from 20 million in 2022 to 35 million by 2050 and cancer causing some ten million deaths each year.
  • The maturation of liquid-biopsy and multiomic technologies is enabling detection of many cancer types from a single blood draw, including cancers that lack any recommended screening test.
  • Large registrational trials are building clinical evidence, with GRAIL's PATHFINDER 2 study showing that adding Galleri to standard screening increased the cancer detection rate over seven-fold.
  • Accelerating regulatory engagement, including FDA Breakthrough Device designations and GRAIL's 2026 premarket approval submission for Galleri, is moving MCED toward formal approval and reimbursement.
  • Growing payer, employer, and health-system interest, including self-insured employers adding MCED to wellness benefits, is expanding commercial access.
  • Advances in artificial intelligence are improving the detection of subtle cancer signals from methylation, fragmentomics, and multiomic data, enhancing accuracy and tissue-of-origin prediction.
  • The convergence of cancer burden, liquid-biopsy maturation, clinical evidence, regulatory progress, and payer interest is expected to sustain strong double-digit growth through 2034.

Key Companies in Multi-Cancer Early Detection Market

The competitive landscape is led by the following active developers and providers:

  • GRAIL, Inc.
  • Exact Sciences Corporation
  • Guardant Health, Inc.
  • Freenome Holdings, Inc.
  • Illumina, Inc.
  • F. Hoffmann-La Roche Ltd (Foundation Medicine)
  • Burning Rock Biotech Limited
  • Natera, Inc.
  • Singlera Genomics, Inc.
  • Delfi Diagnostics, Inc.

Factors Contributing to the Growth of the Multi-Cancer Early Detection Market

Market Drivers

Rising Global Cancer Burden and Demand for Early Detection

The most powerful driver of the Multi-Cancer Early Detection market is the rising global cancer burden and the strong link between early detection and survival. The International Agency for Research on Cancer recorded 20 million new cancer cases in 2022 and projects 35 million by 2050, while cancer causes some ten million deaths each year and remains a leading cause of mortality worldwide. Most cancers are detected late, when treatment is less effective and survival is lower, and the majority of cancer types lack any recommended screening test. Detecting cancer at an earlier stage dramatically improves outcomes and reduces treatment cost, as early-stage therapy is far less expensive than late-stage care. MCED tests address this gap by screening for many cancers at once from a single blood draw, including cancers with no current screening pathway. As cancer incidence climbs with aging populations and lifestyle and environmental factors, demand for earlier, broader detection expands, anchoring market growth through 2034.

Maturation of Liquid Biopsy and Multiomic Technologies

The rapid maturation of liquid-biopsy and multiomic technologies is a central growth engine. Advances in next-generation sequencing, cell-free DNA methylation profiling, fragmentomics, and multi-analyte panels that combine DNA, RNA, protein, and epigenomic markers now enable detection of many cancer types from a single, non-invasive blood sample. Liquid biopsy is especially attractive for primary-care and wellness screening, where invasive tissue biopsies are impractical, and flagship tests such as Galleri detect signals from over fifty cancer types from one blood draw. Falling sequencing costs, improved multiplexing, and new biomarker discoveries continue to raise sensitivity and specificity while lowering price, expanding the range of detectable cancers and the populations that can be screened. As these technologies mature and scale, MCED tests become more accurate, affordable, and accessible, directly driving adoption across clinical and screening settings through the forecast period.

Market Restraints

Despite strong momentum, the Multi-Cancer Early Detection market faces material constraints. High test cost is the primary barrier, as list prices, often between several hundred and over one thousand dollars per test, remain above the comfort zone for population-wide screening, and a leading test lists near USD 949, a figure payers classify as premium relative to mammography or stool-based tests. Limited reimbursement compounds this challenge, as most MCED tests are sold as self-pay laboratory-developed tests without broad payer or Medicare coverage, leaving older adults with the highest cancer incidence often paying out of pocket, and proposed Medicare coverage legislation has not yet been enacted. The absence of FDA approval for most tests constrains adoption, reimbursement, and clinical guideline inclusion, and regulatory pathways are still evolving. Clinical concerns persist, including the risk of false positives that trigger costly and anxiety-inducing confirmatory workups, false negatives that may provide false reassurance, lower sensitivity for early-stage disease, and uncertainty about real-world impact on cancer mortality pending long-term outcomes data. The market is also highly competitive, with many developers pursuing different technologies, creating uncertainty about which platforms will achieve durable clinical and commercial success. Infrastructure limitations, uneven awareness among clinicians and patients, and data-privacy and equity considerations further temper adoption, particularly in emerging markets. Together, these cost, reimbursement, regulatory, clinical, and infrastructure barriers moderate the pace of growth, even as the underlying drivers of cancer burden and liquid-biopsy innovation remain firmly intact.

Multi-Cancer Early Detection Market Segment Analysis

The Multi-Cancer Early Detection Market by Technology (Liquid Biopsy, Gene Panel, Protein-Based and Multiomic, Others), Test Type (Laboratory-Developed Tests, Regulatory-Approved Tests), Sample Type (Blood, Urine, Saliva and Others), End User (Hospitals and Clinics, Diagnostic Laboratories, Academic and Research Institutes, Others), and Geography (North America, Europe, Asia-Pacific, Rest of World).

By Technology

Dominant Subsegment: Liquid Biopsy. The liquid biopsy category is expected to dominate the market.

Dominant: Liquid Biopsy ~ 61%

The liquid biopsy segment accounted for 61% of the Multi-Cancer Early Detection market in 2025. Liquid biopsy is the leading technology because it enables detection of multiple cancer signals from a single, non-invasive blood sample, making it the natural foundation for population-scale, repeatable early-cancer screening. By analyzing cell-free DNA methylation, fragmentomics, mutations, and other tumor-derived markers, liquid biopsy detects a cancer signal and often predicts its tissue of origin across many cancer types at once, including cancers with no recommended screening test. The segment is anchored by flagship tests built entirely on liquid biopsy, such as Galleri, which screens for signals from over fifty cancer types from one blood draw, and by the large registrational trials and regulatory submissions concentrated on blood-based platforms. Liquid biopsy's non-invasive nature suits primary-care and wellness screening where tissue biopsy is impractical. While gene panels, protein-based and multiomic approaches, and other technologies expand the field, the scalability, repeatability, and clinical momentum of liquid biopsy secure its leadership across the forecast period.

By Test Type

Dominant Subsegment: Laboratory-Developed Tests. The laboratory-developed tests category is expected to dominate the market.

Dominant: Laboratory-Developed Tests ~ 68%

The laboratory-developed tests segment accounted for 68% of the Multi-Cancer Early Detection market in 2025. Laboratory-developed tests are the leading test type because they provide a faster route to market, allowing MCED developers to commercialize through CLIA-certified laboratories without first obtaining FDA approval, which most current tests have not yet secured. Leading MCED products, including Galleri and Cancerguard, are offered today as self-pay laboratory-developed tests, generating real-world evidence and revenue while registrational trials and regulatory submissions proceed. This pathway has enabled rapid commercial launch, large clinical datasets, and early payer and employer engagement, sustaining the segment's dominance. At the same time, regulatory-approved tests are expected to grow rapidly as FDA submissions advance, exemplified by GRAIL's premarket approval application for Galleri and the breakthrough designations held by several platforms, because formal approval is widely viewed as the trigger for broad payer and Medicare coverage. While the regulatory-approved segment is the fastest-growing, laboratory-developed tests retain clear leadership in 2025 on the strength of their established commercial role.

By End User

Dominant Subsegment: Hospitals and Clinics. The hospitals and clinics category is expected to dominate the market.

Dominant: Hospitals and Clinics ~ 46%

The hospitals and clinics segment accounted for 46% of the Multi-Cancer Early Detection market in 2025. Hospitals and clinics are the leading end user because they serve as the primary point of contact for cancer screening, risk assessment, and the diagnostic workup that follows a positive MCED result. Physicians in hospital and clinic settings order MCED tests, counsel patients, integrate results into care, and coordinate confirmatory imaging and follow-up, making these settings central to clinical adoption. Integration of MCED ordering and results into electronic health record platforms further embeds testing into routine hospital and clinic workflows. Diagnostic laboratories are a large and fast-growing end user, as CLIA-certified labs perform the complex sequencing and analysis underlying MCED and large lab networks partner with developers to expand access, while academic and research institutes remain critical for clinical validation, biomarker discovery, and trial conduct. While diagnostic laboratories and research settings grow quickly, the clinical centrality of hospitals and clinics secures their leadership across the forecast period.

Multi-Cancer Early Detection Market Region Analysis

Dominant Region: North America

North America accounted for 58% of the global Multi-Cancer Early Detection market revenue in 2025, representing the highest regional market share globally. The region's dominance reflects a robust biotechnology-innovation ecosystem, strong venture capital investment, early regulatory engagement, high cancer-screening awareness, and the presence of the leading MCED developers, particularly in the United States. North America is home to GRAIL, Exact Sciences, Guardant Health, and Freenome, all advancing MCED platforms through clinical validation and commercialization, and benefits from academic medical centers, clinical-research networks, and payers and employers willing to explore coverage for preventive diagnostics. The region leads in registrational trials, exemplified by PATHFINDER 2, and in regulatory milestones, including FDA Breakthrough Device designations and GRAIL's premarket approval submission for Galleri. Self-insured employers and insurers are adding MCED to benefits, and extensive draw and laboratory networks enable nationwide distribution. Deep innovation, capital, and regulatory engagement anchor the region's continued leadership across the forecast period.

Dominant: North America ~ 58% (Largest)

Fastest Growing Region: Asia-Pacific

Asia-Pacific is the fastest-growing region in the Multi-Cancer Early Detection market. The region's elevated CAGR is driven by a large and rising cancer burden, expanding government cancer-screening initiatives, growing healthcare investment, and strong regional developers across China, Japan, India, South Korea, and Singapore. China hosts active MCED developers such as Burning Rock and Singlera Genomics, which pursue cost-effective, scalable platforms and cross-border regulatory strategies, while Japan emphasizes preventive cancer strategies and has begun landmark national evaluations of MCED tests. Rising awareness, expanding access to advanced diagnostics, and government measures to improve early cancer detection accelerate adoption, and partnerships are extending blood-based screening across the region. The combination of high disease burden, government support, and local innovation positions Asia-Pacific as the principal source of incremental growth over the forecast period.

Regional Commentary

North America

North America accounted for 58% of the global Multi-Cancer Early Detection market revenue in 2025. The United States dominates on the strength of its developer base, venture capital, early regulatory engagement, high screening awareness, registrational trials, and growing employer and payer interest, while Canada contributes through participation in major trials and academic research.

Europe

Europe is a large and advanced regional market, led by the United Kingdom, Germany, France, Italy, and Spain. Growth is anchored by the landmark NHS-Galleri trial in the United Kingdom, one of the largest prospective MCED studies, alongside strong public health systems, national cancer strategies, and academic research that support evidence generation and gradual adoption across the region.

Asia-Pacific

Asia-Pacific is the fastest-growing region, propelled by a large and rising cancer burden, expanding government screening initiatives, growing healthcare investment, and strong regional developers across China, Japan, India, South Korea, and Singapore. Local innovators pursue cost-effective platforms, while national evaluations and partnerships extend blood-based early detection across the region.

Rest of World

The Rest of World region, spanning Latin America, the Middle East, and Africa, is an emerging frontier. A rising cancer burden and growing interest in preventive screening are creating early demand, with Gulf states adopting Western assays for premium clinics and some private insurers trialing MCED coverage, while broad public adoption awaits stronger reimbursement, infrastructure, and local evidence across these markets.

Multi-Cancer Early Detection Market Competitive Landscape

The Multi-Cancer Early Detection market is classified as Moderately Concentrated. A small group of well-capitalized leaders with large clinical datasets, including GRAIL, Exact Sciences, and Guardant Health, holds the majority of share, given that clinical-evidence generation demands substantial capital and favors incumbents, while a broad and active field of developers, including Freenome, Foundation Medicine, Burning Rock, Singlera Genomics, and Delfi Diagnostics, pursues differentiated technologies, intensifying competition and innovation across the field.

The competitive landscape can be evaluated across the following dimensions:

  • Market concentration: Moderately concentrated, with capital-intensive clinical-evidence generation favoring well-funded leaders alongside many emerging developers.
  • Leading players: GRAIL, Exact Sciences, and Guardant Health anchor the top tier through large datasets, commercial scale, and regulatory progress.
  • Geographic reach: Leaders operate national draw and laboratory networks and expand internationally, with regional players strong in China, Japan, and Southeast Asia.
  • Product portfolio strength: Top players hold validated pan-cancer or blood-based screening tests, often alongside single-cancer and precision-oncology portfolios.
  • Pipeline and evidence strength: Large registrational trials such as PATHFINDER 2 and NHS-Galleri, and breakthrough designations, are decisive competitive assets.
  • Strategic partnerships: Collaborations with laboratory networks, health systems, employers, electronic health record platforms, and international partners extend reach.
  • M&A activity: Consolidation is active, including GRAIL's spin-off from Illumina and Abbott's planned acquisition of Exact Sciences.
  • Regulatory strength: FDA Breakthrough Device designations and premarket approval submissions, such as GRAIL's for Galleri, are key differentiators.
  • Innovation focus: Methylation and fragmentomics, multiomics, AI-driven signal detection and tissue-of-origin prediction, and lower-cost, scalable assays.

Multi-Cancer Early Detection Market Recent Developmental Activities

In April 2026, GRAIL, Inc., announced integration of the Galleri test into the Epic electronic health record platform, enabling ordering and result access across hundreds of health systems and expanding point-of-care access. Strategic significance: Embeds MCED into routine clinical workflows and broadens physician adoption at scale.

In January 2026, GRAIL, Inc., completed its modular premarket approval submission to the FDA for the Galleri multi-cancer early detection test, which holds Breakthrough Device designation, drawing on PATHFINDER 2 and NHS-Galleri data. Strategic significance: Advances the first major MCED test toward formal FDA approval, a key trigger for payer and Medicare coverage.

Multi-Cancer Early Detection Market Segmentation

Multi-Cancer Early Detection Market by Technology

  • Liquid Biopsy
  • Gene Panel
  • Protein-Based and Multiomic
  • Others

Multi-Cancer Early Detection Market by Test Type

  • Laboratory-Developed Tests
  • Regulatory-Approved Tests

Multi-Cancer Early Detection Market by Sample Type

  • Blood
  • Urine
  • Saliva and Others

Multi-Cancer Early Detection Market by Cancer Type

  • Screened Cancers
  • Colorectal Cancer
  • Lung Cancer
  • Breast Cancer
  • Prostate Cancer
  • Other and Unscreened Cancers

Multi-Cancer Early Detection Market by End User

  • Hospitals and Clinics
  • Diagnostic Laboratories
  • Academic and Research Institutes
  • Others

Multi-Cancer Early Detection Market by Geography

  • North America Multi-Cancer Early Detection Market
  • United States Multi-Cancer Early Detection Market Size in USD million (2023-2034)
  • Canada Multi-Cancer Early Detection Market Size in USD million (2023-2034)
  • Mexico Multi-Cancer Early Detection Market Size in USD million (2023-2034)
  • Europe Multi-Cancer Early Detection Market
  • Germany Multi-Cancer Early Detection Market Size in USD million (2023-2034)
  • United Kingdom Multi-Cancer Early Detection Market Size in USD million (2023-2034)
  • France Multi-Cancer Early Detection Market Size in USD million (2023-2034)
  • Italy Multi-Cancer Early Detection Market Size in USD million (2023-2034)
  • Spain Multi-Cancer Early Detection Market Size in USD million (2023-2034)
  • Rest of Europe Multi-Cancer Early Detection Market Size in USD million (2023-2034)
  • Asia-Pacific Multi-Cancer Early Detection Market
  • China Multi-Cancer Early Detection Market Size in USD million (2023-2034)
  • Japan Multi-Cancer Early Detection Market Size in USD million (2023-2034)
  • India Multi-Cancer Early Detection Market Size in USD million (2023-2034)
  • Australia Multi-Cancer Early Detection Market Size in USD million (2023-2034)
  • South Korea Multi-Cancer Early Detection Market Size in USD million (2023-2034)
  • Rest of Asia-Pacific Multi-Cancer Early Detection Market Size in USD million (2023-2034)
  • Rest of the World (RoW) Multi-Cancer Early Detection Market
  • Middle East Multi-Cancer Early Detection Market Size in USD million (2023-2034)
  • Africa Multi-Cancer Early Detection Market Size in USD million (2023-2034)
  • South America Multi-Cancer Early Detection Market Size in USD million (2023-2034)

Key Takeaways from the Multi-Cancer Early Detection Market Report Study

  • Market size analysis for the current multi-cancer early detection market size (2025), and market forecast for 9 years (2026 to 2034).
  • Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures that happened over the last 3 years.
  • Key companies dominating the global multi-cancer early detection market.
  • Various opportunities available for competitors in the multi-cancer early detection market space.
  • What are the top-performing segments in 2025? How will these segments perform in 2034?
  • Which are the top-performing regions and countries in the current multi-cancer early detection market scenario?
  • Which are the regions and countries where companies should concentrate their opportunities for multi-cancer early detection market growth in the future?

Target audience who can benefit from this multi-cancer early detection market report study

  • Multi-Cancer Early Detection product providers
  • Research organizations and consulting companies
  • Multi-Cancer Early Detection-related organizations, associations, forums, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and traders dealing in multi-cancer early detection
  • Various end-users who want to know more about the multi-cancer early detection market and the latest technological developments in the multi-cancer early detection market.

Frequently Asked Questions:

Q1. What is the growth rate of the Multi-Cancer Early Detection market?

The Multi-Cancer Early Detection market is projected to expand at a CAGR of 15.9% during the forecast period from 2026-2034.

Q2. What is the market size of the Multi-Cancer Early Detection market?

The Multi-Cancer Early Detection market is estimated at USD 1.55 billion in 2025 and is projected to reach USD 5.85 billion by 2034.

Q3. Which region dominates the Multi-Cancer Early Detection market?

North America dominated the Multi-Cancer Early Detection market with a 58% share of global revenue in 2025, supported by a robust biotechnology ecosystem, strong venture investment, early regulatory engagement, high screening awareness, and the presence of leading developers such as GRAIL, Exact Sciences, and Guardant Health. Asia-Pacific is the fastest-growing region over the forecast period.

Q4. What are the key drivers of the Multi-Cancer Early Detection market?

The principal drivers are the rising global cancer burden, with the International Agency for Research on Cancer projecting cancer cases to rise from 20 million in 2022 to 35 million by 2050; the maturation of liquid-biopsy and multiomic technologies; growing clinical evidence from large trials such as PATHFINDER 2 and NHS-Galleri; accelerating FDA engagement, including breakthrough designations and GRAIL's premarket approval submission; and expanding payer, employer, and health-system adoption.

Q5. Who are the major players in the Multi-Cancer Early Detection market?

The major players include GRAIL, Inc., Exact Sciences Corporation, Guardant Health, Inc., Freenome Holdings, Inc., Illumina, Inc., F. Hoffmann-La Roche Ltd (Foundation Medicine), Burning Rock Biotech Limited, Natera, Inc., Singlera Genomics, Inc., and Delfi Diagnostics, Inc., among other active developers profiled in the Competitive Landscape section. GRAIL leads with Galleri and the largest MCED clinical dataset, while Guardant Health and Exact Sciences advance blood-based screening platforms.

Table of Contents

1. Multi-Cancer Early Detection Market Report Introduction

  • 1.1 Scope of the Study
  • 1.2 Market Segmentation
  • 1.3 Market Assumptions

2. Multi-Cancer Early Detection Market Executive Summary

  • 2.1 Market at a Glance

3. Multi-Cancer Early Detection Market Key Factors Analysis

  • 3.1 Multi-Cancer Early Detection Market Drivers
    • 3.1.1 Rising Global Cancer Burden and Early Detection
    • 3.1.2 Maturation of Liquid Biopsy and Multiomics
    • 3.1.3 Growing Clinical Evidence and Regulatory Engagement
    • 3.1.4 Payer, Employer, and Health-System Adoption
  • 3.2 Multi-Cancer Early Detection Market Restraints and Challenges
    • 3.2.1 High Test Cost and Limited Reimbursement
    • 3.2.2 Regulatory and Clinical-Validation Barriers
    • 3.2.3 False Positives, False Negatives, and Confirmatory Workup
  • 3.3 Multi-Cancer Early Detection Market Opportunities
    • 3.3.1 FDA Approval, Reimbursement, and Medicare Coverage
    • 3.3.2 Emerging-Market and Preventive-Screening Expansion

4. Impact Analysis: AI, Geopolitical, Trade, and Economic Developments

5. Regulatory Analysis

  • 5.1 United States
  • 5.2 Europe
  • 5.3 Japan
  • 5.4 China

6. Multi-Cancer Early Detection Market Porter's Five Forces Analysis

  • 6.1 Bargaining Power of Suppliers
  • 6.2 Bargaining Power of Buyers
  • 6.3 Threat of New Entrants
  • 6.4 Threat of Substitutes
  • 6.5 Competitive Rivalry

7. Multi-Cancer Early Detection Market Assessment

  • 7.1 By Technology
    • 7.1.1 Liquid Biopsy
    • 7.1.2 Gene Panel
    • 7.1.3 Protein-Based and Multiomic
    • 7.1.4 Others
  • 7.2 By Test Type
    • 7.2.1 Laboratory-Developed Tests
    • 7.2.2 Regulatory-Approved Tests
  • 7.3 By Sample Type
    • 7.3.1 Blood
    • 7.3.2 Urine
    • 7.3.3 Saliva and Others
  • 7.4 By End User
    • 7.4.1 Hospitals and Clinics
    • 7.4.2 Diagnostic Laboratories
    • 7.4.3 Academic and Research Institutes
    • 7.4.4 Others
  • 7.5 By Geography
    • 7.5.1 North America
      • 7.5.1.1 United States Multi-Cancer Early Detection Market Size in USD million (2023-2034)
      • 7.5.1.2 Canada Multi-Cancer Early Detection Market Size in USD million (2023-2034)
      • 7.5.1.3 Mexico Multi-Cancer Early Detection Market Size in USD million (2023-2034)
    • 7.5.2 Europe
      • 7.5.2.1 Germany Multi-Cancer Early Detection Market Size in USD million (2023-2034)
      • 7.5.2.2 United Kingdom Multi-Cancer Early Detection Market Size in USD million (2023-2034)
      • 7.5.2.3 France Multi-Cancer Early Detection Market Size in USD million (2023-2034)
      • 7.5.2.4 Italy Multi-Cancer Early Detection Market Size in USD million (2023-2034)
      • 7.5.2.5 Spain Multi-Cancer Early Detection Market Size in USD million (2023-2034)
      • 7.5.2.6 Rest of Europe Multi-Cancer Early Detection Market Size in USD million (2023-2034)
    • 7.5.3 Asia-Pacific
      • 7.5.3.1 China Multi-Cancer Early Detection Market Size in USD million (2023-2034)
      • 7.5.3.2 Japan Multi-Cancer Early Detection Market Size in USD million (2023-2034)
      • 7.5.3.3 India Multi-Cancer Early Detection Market Size in USD million (2023-2034)
      • 7.5.3.4 Australia Multi-Cancer Early Detection Market Size in USD million (2023-2034)
      • 7.5.3.5 South Korea Multi-Cancer Early Detection Market Size in USD million (2023-2034)
      • 7.5.3.6 Rest of Asia-Pacific Multi-Cancer Early Detection Market Size in USD million (2023-2034)
    • 7.5.4 Rest of World
      • 7.5.4.1 Middle East Multi-Cancer Early Detection Market Size in USD million (2023-2034)
      • 7.5.4.2 Africa Multi-Cancer Early Detection Market Size in USD million (2023-2034)
      • 7.5.4.3 South America Multi-Cancer Early Detection Market Size in USD million (2023-2034)

8. Multi-Cancer Early Detection Market Competitive Landscape

  • 8.1 Market Concentration and Structure
  • 8.2 Competitive Positioning and Market Share Analysis (Premium Offering)

9. Multi-Cancer Early Detection Market Startup Funding and Investment Trends

10. Multi-Cancer Early Detection Market Company and Product Profiles

  • 10.1 GRAIL, Inc.
    • 10.1.1 Company Overview
    • 10.1.2 Company Snapshot
    • 10.1.3 Financial Overview
    • 10.1.4 Product Portfolio
    • 10.1.5 Strategic Initiatives / Entropy
  • 10.2 Exact Sciences Corporation
    • 10.2.1 Company Overview
    • 10.2.2 Company Snapshot
    • 10.2.3 Financial Overview
    • 10.2.4 Product Portfolio
    • 10.2.5 Strategic Initiatives / Entropy
  • 10.3 Guardant Health, Inc.
    • 10.3.1 Company Overview
    • 10.3.2 Company Snapshot
    • 10.3.3 Financial Overview
    • 10.3.4 Product Portfolio
    • 10.3.5 Strategic Initiatives / Entropy
  • 10.4 Freenome Holdings, Inc.
    • 10.4.1 Company Overview
    • 10.4.2 Company Snapshot
    • 10.4.3 Financial Overview
    • 10.4.4 Product Portfolio
    • 10.4.5 Strategic Initiatives / Entropy
  • 10.5 Illumina, Inc.
    • 10.5.1 Company Overview
    • 10.5.2 Company Snapshot
    • 10.5.3 Financial Overview
    • 10.5.4 Product Portfolio
    • 10.5.5 Strategic Initiatives / Entropy
  • 10.6 F. Hoffmann-La Roche Ltd (Foundation Medicine)
    • 10.6.1 Company Overview
    • 10.6.2 Company Snapshot
    • 10.6.3 Financial Overview
    • 10.6.4 Product Portfolio
    • 10.6.5 Strategic Initiatives / Entropy
  • 10.7 Burning Rock Biotech Limited
    • 10.7.1 Company Overview
    • 10.7.2 Company Snapshot
    • 10.7.3 Financial Overview
    • 10.7.4 Product Portfolio
    • 10.7.5 Strategic Initiatives / Entropy
  • 10.8 Natera, Inc.
    • 10.8.1 Company Overview
    • 10.8.2 Company Snapshot
    • 10.8.3 Financial Overview
    • 10.8.4 Product Portfolio
    • 10.8.5 Strategic Initiatives / Entropy
  • 10.9 Singlera Genomics, Inc.
    • 10.9.1 Company Overview
    • 10.9.2 Company Snapshot
    • 10.9.3 Financial Overview
    • 10.9.4 Product Portfolio
    • 10.9.5 Strategic Initiatives / Entropy
  • 10.10 Delfi Diagnostics, Inc.
    • 10.10.1 Company Overview
    • 10.10.2 Company Snapshot
    • 10.10.3 Financial Overview
    • 10.10.4 Product Portfolio
    • 10.10.5 Strategic Initiatives / Entropy

For illustrative purposes, only the top 10 companies are listed in the Table of Contents. The report may include analysis and references to additional companies where relevant to the market assessment.

11. KOL Views

12. Project Approach

13. About DelveInsight

14. Disclaimer and Contact Us

List of Tables

  • Table 1: Multi-Cancer Early Detection Market in Global (2023-2034)
  • Table 2: Multi-Cancer Early Detection Market in Global by Technology (2023-2034)
  • Table 3: Multi-Cancer Early Detection Market in Global by Test Type (2023-2034)
  • Table 4: Multi-Cancer Early Detection Market in Global by Sample Type (2023-2034)
  • Table 5: Multi-Cancer Early Detection Market in Global by End User (2023-2034)
  • Table 6: Multi-Cancer Early Detection Market in Global by Geography (2023-2034)
  • Table 7: Multi-Cancer Early Detection Market in North America (2023-2034)
  • Table 8: Multi-Cancer Early Detection Market in the United States (2023-2034)
  • Table 9: Multi-Cancer Early Detection Market in Canada (2023-2034)
  • Table 10: Multi-Cancer Early Detection Market in Mexico (2023-2034)
  • Table 11: Multi-Cancer Early Detection Market in Europe (2023-2034)
  • Table 12: Multi-Cancer Early Detection Market in Germany (2023-2034)
  • Table 13: Multi-Cancer Early Detection Market in United Kingdom (2023-2034)
  • Table 14: Multi-Cancer Early Detection Market in France (2023-2034)
  • Table 15: Multi-Cancer Early Detection Market in Italy (2023-2034)
  • Table 16: Multi-Cancer Early Detection Market in Spain (2023-2034)
  • Table 17: Multi-Cancer Early Detection Market in the Rest of Europe (2023-2034)
  • Table 18: Multi-Cancer Early Detection Market in Asia-Pacific (2023-2034)
  • Table 19: Multi-Cancer Early Detection Market in China (2023-2034)
  • Table 20: Multi-Cancer Early Detection Market in Japan (2023-2034)
  • Table 21: Multi-Cancer Early Detection Market in India (2023-2034)
  • Table 22: Multi-Cancer Early Detection Market in Australia (2023-2034)
  • Table 23: Multi-Cancer Early Detection Market in South Korea (2023-2034)
  • Table 24: Multi-Cancer Early Detection Market in Rest of Asia-Pacific (2023-2034)
  • Table 25: Multi-Cancer Early Detection Market in the Rest of the World (2023-2034)
  • Table 26: Multi-Cancer Early Detection Market in the Middle East (2023-2034)
  • Table 27: Multi-Cancer Early Detection Market in Africa (2023-2034)
  • Table 28: Multi-Cancer Early Detection Market in South America (2023-2034)
  • Table 29: Competitive Landscape
  • Table 30: Startup Funding and Investment Trends

List of Figures

  • Figure 1: Multi-Cancer Early Detection Market Drivers
  • Figure 2: Multi-Cancer Early Detection Market Restraints
  • Figure 3: Multi-Cancer Early Detection Market Opportunities
  • Figure 4: Impact Analysis: AI, Geopolitical, Trade, and Economic Developments
  • Figure 5: Regulatory Analysis (US, EU, Japan, China)
  • Figure 6: Porter's Five Forces Analysis
  • Figure 7: Competitive Analysis
  • Figure 8: Multi-Cancer Early Detection Market in Global (2023-2034)
  • Figure 9: Multi-Cancer Early Detection Market in Global by Technology (2023-2034)
  • Figure 10: Multi-Cancer Early Detection Market in Global by Test Type (2023-2034)
  • Figure 11: Multi-Cancer Early Detection Market in Global by Sample Type (2023-2034)
  • Figure 12: Multi-Cancer Early Detection Market in Global by End User (2023-2034)
  • Figure 13: Multi-Cancer Early Detection Market in Global by Geography (2023-2034)
  • Figure 14: Multi-Cancer Early Detection Market in North America (2023-2034)
  • Figure 15: Multi-Cancer Early Detection Market in the United States (2023-2034)
  • Figure 16: Multi-Cancer Early Detection Market in Canada (2023-2034)
  • Figure 17: Multi-Cancer Early Detection Market in Mexico (2023-2034)
  • Figure 18: Multi-Cancer Early Detection Market in Europe (2023-2034)
  • Figure 19: Multi-Cancer Early Detection Market in Germany (2023-2034)
  • Figure 20: Multi-Cancer Early Detection Market in United Kingdom (2023-2034)
  • Figure 21: Multi-Cancer Early Detection Market in France (2023-2034)
  • Figure 22: Multi-Cancer Early Detection Market in Italy (2023-2034)
  • Figure 23: Multi-Cancer Early Detection Market in Spain (2023-2034)
  • Figure 24: Multi-Cancer Early Detection Market in the Rest of Europe (2023-2034)
  • Figure 25: Multi-Cancer Early Detection Market in Asia-Pacific (2023-2034)
  • Figure 26: Multi-Cancer Early Detection Market in China (2023-2034)
  • Figure 27: Multi-Cancer Early Detection Market in Japan (2023-2034)
  • Figure 28: Multi-Cancer Early Detection Market in India (2023-2034)
  • Figure 29: Multi-Cancer Early Detection Market in Australia (2023-2034)
  • Figure 30: Multi-Cancer Early Detection Market in South Korea (2023-2034)
  • Figure 31: Multi-Cancer Early Detection Market in Rest of Asia-Pacific (2023-2034)
  • Figure 32: Multi-Cancer Early Detection Market in the Rest of the World (2023-2034)
  • Figure 33: Multi-Cancer Early Detection Market in the Middle East (2023-2034)
  • Figure 34: Multi-Cancer Early Detection Market in Africa (2023-2034)
  • Figure 35: Multi-Cancer Early Detection Market in South America (2023-2034)
  • Figure 36: Competitive Landscape
  • Figure 37: Startup Funding and Investment Trends